Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 15/20 | 0.63 |
| ▸ | NR4A1 | P22736 | 3/20 | 0.63 |
| ▸ | NR4A3 | Q92570 | 3/20 | 0.63 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.60 |
| ▸ | RXRA | P19793 | 7/20 | 0.59 |
| ▸ | RXRB | P28702 | 6/20 | 0.59 |
| ▸ | RXRG | P48443 | 4/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.59 |
| ▸ | C5 | P01031 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.59 |
| ▸ | DRD2 | P14416 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.59 |
| ▸ | HTR2A | P28223 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11719710 | 0.86 | NR4A2 (0.65) | NR4A2NR4A1NR4A3AOC3RXRA | |
| SCHEMBL14867495 | 0.85 | NR4A2 (0.73) | NR4A2NR4A1NR4A3AOC3RXRA | |
| SCHEMBL2760386 | 0.81 | NR4A2 (0.63) | NR4A2NR4A1NR4A3AOC3RXRA | |
| SCHEMBL8929931 | 0.81 | NR4A2 (0.68) | NR4A2NR4A1NR4A3AOC3RXRA | |
| SCHEMBL11718919 | 0.81 | NR4A2 (0.63) | NR4A2NR4A1NR4A3AOC3RXRA | |
| SCHEMBL8446239 | 0.81 | NR4A2 (0.68) | NR4A2NR4A1NR4A3AOC3RXRA | |
| SCHEMBL8113859 | 0.80 | NR4A2 (0.66) | NR4A2NR4A1NR4A3AOC3RXRA | |
| Hydrochloric Acid SCHEMBL11714388 | 0.80 | NR4A2 (0.61) | NR4A2NR4A1NR4A3AOC3RXRA | |
| SCHEMBL7492453 | 0.79 | NR4A2 (0.66) | NR4A2NR4A1NR4A3AOC3RXRA | |
| SCHEMBL13653143 | 0.79 | NR4A2 (0.65) | NR4A2NR4A1NR4A3AOC3RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118344239-A | Method for efficiently constructing carbon-carbon bond by nitrogen deletion reaction | 南京大学 | 2024-07-16 | — | — | CN | claimed |
| CN-118344239-A | Method for efficiently constructing carbon-carbon bond by nitrogen deletion reaction | 南京大学 | 2024-07-16 | — | — | CN | disclosed |
| CN-118344239-A | Method for efficiently constructing carbon-carbon bond by nitrogen deletion reaction | 南京大学 | 2024-07-16 | — | — | CN | disclosed |
| US-8735398-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-27 | — | — | US | disclosed |
| US-8735398-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-27 | — | — | US | disclosed |
| US-20130085147-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | US | disclosed |
| US-20130085147-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | US | disclosed |
| US-8362020-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362020-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-29 | — | — | US | disclosed |
| US-20110294819-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-01 | — | — | US | disclosed |
| US-5972965-A | USEFUL FOR INHIBITION OF PLATELET AGGREGATION, VASODILATION, ANTIHYPERTENSIVE ACTIVITY AND PROSTAGLANDIN AGONIST | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-10-26 | — | — | US | disclosed |
| EP-0582164-B1 | Adenosine re-uptake inhibiting derivatives of diphenyl oxazoles, thiazoles and imidazoles | BRISTOL MYERS SQUIBB CO (US) | 1998-12-23 | — | — | EP | disclosed |
| CN-1196726-A | 4,5-diaryl oxazole derivatives | FUJISAWA PHARMACEUTICAL CO (JP) | 1998-10-21 | — | — | CN | disclosed |
| EP-0842161-A1 | 4,5-DIARYL OXAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-05-20 | — | — | EP | disclosed |
| WO-1997003973-A1 | 4,5-DIARYL OXAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-02-06 | — | — | WO | disclosed |
| US-5382584-A | Antiischemic agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-01-17 | — | — | US | disclosed |
| US-5362879-A | 4-5-diphenyloxazole derivatives as inhibitors of blood platelet aggregation | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-11-08 | — | — | US | disclosed |
| EP-0582164-A1 | Adenosine re-uptake inhibiting derivatives of diphenyl oxazoles, thiazoles and imidazoles | Bristol-Myers Squibb Company (US) | 1994-02-09 | — | — | EP | disclosed |
| US-5262540-A | FOR INHIBITION OF BLOOD PLATELET AGGREGATION IN MAMMALS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1993-11-16 | — | — | US | disclosed |
| EP-0434034-A1 | Oxazole derivatives | Bristol-Myers Squibb Company (US) | 1991-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294819-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, GTF3C1 | NR4A2 3701/4885NR4A1 3394/4885NR4A3 3140/4885 |
| US-20130085147-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, GTF3C1 | NR4A2 3701/4885NR4A1 3394/4885NR4A3 3140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.